| Dr Chrystel Therese Venturini, MD | |
|
3417 Ensign Rd Ne, Olympia, WA 98506-5064 | |
| (360) 493-4600 | |
| (360) 493-4603 |
| Full Name | Dr Chrystel Therese Venturini |
|---|---|
| Gender | Female |
| Speciality | Diagnostic Radiology |
| Experience | 30 Years |
| Location | 3417 Ensign Rd Ne, Olympia, Washington |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396882106 | NPI | - | NPPES |
| 000000697063 | Other | KY | ANTHEM- KENTUCKY CHILDREN'S RADIOLOGISTS |
| 0379437 | Other | WA | L&I-SOUTH SOUND RADIOLOGY |
| 122797 | Other | KY | SIHO- KENTUCKY CHILDREN'S RADIOLOGISTS |
| 000057094W | Other | KY | HUMANA- KENTUCKY CHILDREN'S RADIOLOGISTS |
| 0384449 | Other | WA | L&I-RADIA |
| 2008419 | Medicaid | WA | |
| 7100170330 | Medicaid | KY | |
| 201018220 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | MD00040907 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence St Peter Hospital | Olympia, WA | Hospital |
| Providence Centralia Hospital | Centralia, WA | Hospital |
| Arbor Health Morton Hospital | Morton, WA | Hospital |
| Mason General Hospital & Family Of Clinics | Shelton, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| South Sound Radiologists Inc P S | 1254229305 | 58 |
| Radia Inc P S | 9931012812 | 254 |
News Archive
Mylan Inc. today confirmed that its majority-owned subsidiary, Matrix Laboratories Ltd., has been sued by Daiichi Sankyo in connection with Amlodipine Besylate/Olmesartan Medoxomil Tablets, 5 mg/20 mg, 10 mg/20 mg, 5 mg/40 mg and 10 mg/40 mg, the generic version of Daiichi Sankyo's Azor Tablets.
Following positive preliminary data, Octapharma USA is extending funding for an investigator-initiated study (IIS) focused on treating the most critical patients at the heart of the coronavirus pandemic, those experiencing hypoxia and who are at the highest risk of requiring mechanical ventilation.
DePuy Synthes*, in collaboration with LifeNet Health®, launches ViviGen Formable™ Cellular Bone Matrix**, a second generation cellular allograft used to assist in the formation of bone during spinal fusion surgery. ViviGen Formable augments the DePuy Synthes biomaterials portfolio and joins the first generation, ViviGen® Cellular Bone Matrix, which launched in late 2014. With both ViviGen and ViviGen Formable, surgeons may now choose a preferred handling option based on the needs of each surgical case.
Although more than two fifths of lung cancers are diagnosed in patients over 70, data from clinical trials on the safest and most effective treatments for this age group are scarce.
› Verified 4 days ago
| Entity Name | Radia Inc P S |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932196607 PECOS PAC ID: 9931012812 Enrollment ID: O20031106000749 |
News Archive
Mylan Inc. today confirmed that its majority-owned subsidiary, Matrix Laboratories Ltd., has been sued by Daiichi Sankyo in connection with Amlodipine Besylate/Olmesartan Medoxomil Tablets, 5 mg/20 mg, 10 mg/20 mg, 5 mg/40 mg and 10 mg/40 mg, the generic version of Daiichi Sankyo's Azor Tablets.
Following positive preliminary data, Octapharma USA is extending funding for an investigator-initiated study (IIS) focused on treating the most critical patients at the heart of the coronavirus pandemic, those experiencing hypoxia and who are at the highest risk of requiring mechanical ventilation.
DePuy Synthes*, in collaboration with LifeNet Health®, launches ViviGen Formable™ Cellular Bone Matrix**, a second generation cellular allograft used to assist in the formation of bone during spinal fusion surgery. ViviGen Formable augments the DePuy Synthes biomaterials portfolio and joins the first generation, ViviGen® Cellular Bone Matrix, which launched in late 2014. With both ViviGen and ViviGen Formable, surgeons may now choose a preferred handling option based on the needs of each surgical case.
Although more than two fifths of lung cancers are diagnosed in patients over 70, data from clinical trials on the safest and most effective treatments for this age group are scarce.
› Verified 4 days ago
| Entity Name | The Association Of Chrmc And University Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255449963 PECOS PAC ID: 9133032964 Enrollment ID: O20031107000585 |
News Archive
Mylan Inc. today confirmed that its majority-owned subsidiary, Matrix Laboratories Ltd., has been sued by Daiichi Sankyo in connection with Amlodipine Besylate/Olmesartan Medoxomil Tablets, 5 mg/20 mg, 10 mg/20 mg, 5 mg/40 mg and 10 mg/40 mg, the generic version of Daiichi Sankyo's Azor Tablets.
Following positive preliminary data, Octapharma USA is extending funding for an investigator-initiated study (IIS) focused on treating the most critical patients at the heart of the coronavirus pandemic, those experiencing hypoxia and who are at the highest risk of requiring mechanical ventilation.
DePuy Synthes*, in collaboration with LifeNet Health®, launches ViviGen Formable™ Cellular Bone Matrix**, a second generation cellular allograft used to assist in the formation of bone during spinal fusion surgery. ViviGen Formable augments the DePuy Synthes biomaterials portfolio and joins the first generation, ViviGen® Cellular Bone Matrix, which launched in late 2014. With both ViviGen and ViviGen Formable, surgeons may now choose a preferred handling option based on the needs of each surgical case.
Although more than two fifths of lung cancers are diagnosed in patients over 70, data from clinical trials on the safest and most effective treatments for this age group are scarce.
› Verified 4 days ago
| Entity Name | Evergreen Radia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922095694 PECOS PAC ID: 4587568076 Enrollment ID: O20031125000896 |
News Archive
Mylan Inc. today confirmed that its majority-owned subsidiary, Matrix Laboratories Ltd., has been sued by Daiichi Sankyo in connection with Amlodipine Besylate/Olmesartan Medoxomil Tablets, 5 mg/20 mg, 10 mg/20 mg, 5 mg/40 mg and 10 mg/40 mg, the generic version of Daiichi Sankyo's Azor Tablets.
Following positive preliminary data, Octapharma USA is extending funding for an investigator-initiated study (IIS) focused on treating the most critical patients at the heart of the coronavirus pandemic, those experiencing hypoxia and who are at the highest risk of requiring mechanical ventilation.
DePuy Synthes*, in collaboration with LifeNet Health®, launches ViviGen Formable™ Cellular Bone Matrix**, a second generation cellular allograft used to assist in the formation of bone during spinal fusion surgery. ViviGen Formable augments the DePuy Synthes biomaterials portfolio and joins the first generation, ViviGen® Cellular Bone Matrix, which launched in late 2014. With both ViviGen and ViviGen Formable, surgeons may now choose a preferred handling option based on the needs of each surgical case.
Although more than two fifths of lung cancers are diagnosed in patients over 70, data from clinical trials on the safest and most effective treatments for this age group are scarce.
› Verified 4 days ago
| Entity Name | South Sound Radiologists Inc P S |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902990500 PECOS PAC ID: 1254229305 Enrollment ID: O20040309001119 |
News Archive
Mylan Inc. today confirmed that its majority-owned subsidiary, Matrix Laboratories Ltd., has been sued by Daiichi Sankyo in connection with Amlodipine Besylate/Olmesartan Medoxomil Tablets, 5 mg/20 mg, 10 mg/20 mg, 5 mg/40 mg and 10 mg/40 mg, the generic version of Daiichi Sankyo's Azor Tablets.
Following positive preliminary data, Octapharma USA is extending funding for an investigator-initiated study (IIS) focused on treating the most critical patients at the heart of the coronavirus pandemic, those experiencing hypoxia and who are at the highest risk of requiring mechanical ventilation.
DePuy Synthes*, in collaboration with LifeNet Health®, launches ViviGen Formable™ Cellular Bone Matrix**, a second generation cellular allograft used to assist in the formation of bone during spinal fusion surgery. ViviGen Formable augments the DePuy Synthes biomaterials portfolio and joins the first generation, ViviGen® Cellular Bone Matrix, which launched in late 2014. With both ViviGen and ViviGen Formable, surgeons may now choose a preferred handling option based on the needs of each surgical case.
Although more than two fifths of lung cancers are diagnosed in patients over 70, data from clinical trials on the safest and most effective treatments for this age group are scarce.
› Verified 4 days ago
| Entity Name | Swedish Radia Imaging Center At Edmonds Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164494373 PECOS PAC ID: 5496778292 Enrollment ID: O20060106000841 |
News Archive
Mylan Inc. today confirmed that its majority-owned subsidiary, Matrix Laboratories Ltd., has been sued by Daiichi Sankyo in connection with Amlodipine Besylate/Olmesartan Medoxomil Tablets, 5 mg/20 mg, 10 mg/20 mg, 5 mg/40 mg and 10 mg/40 mg, the generic version of Daiichi Sankyo's Azor Tablets.
Following positive preliminary data, Octapharma USA is extending funding for an investigator-initiated study (IIS) focused on treating the most critical patients at the heart of the coronavirus pandemic, those experiencing hypoxia and who are at the highest risk of requiring mechanical ventilation.
DePuy Synthes*, in collaboration with LifeNet Health®, launches ViviGen Formable™ Cellular Bone Matrix**, a second generation cellular allograft used to assist in the formation of bone during spinal fusion surgery. ViviGen Formable augments the DePuy Synthes biomaterials portfolio and joins the first generation, ViviGen® Cellular Bone Matrix, which launched in late 2014. With both ViviGen and ViviGen Formable, surgeons may now choose a preferred handling option based on the needs of each surgical case.
Although more than two fifths of lung cancers are diagnosed in patients over 70, data from clinical trials on the safest and most effective treatments for this age group are scarce.
› Verified 4 days ago
| Entity Name | Radia Imaging Center Holdings Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639653017 PECOS PAC ID: 6305182965 Enrollment ID: O20190118000572 |
News Archive
Mylan Inc. today confirmed that its majority-owned subsidiary, Matrix Laboratories Ltd., has been sued by Daiichi Sankyo in connection with Amlodipine Besylate/Olmesartan Medoxomil Tablets, 5 mg/20 mg, 10 mg/20 mg, 5 mg/40 mg and 10 mg/40 mg, the generic version of Daiichi Sankyo's Azor Tablets.
Following positive preliminary data, Octapharma USA is extending funding for an investigator-initiated study (IIS) focused on treating the most critical patients at the heart of the coronavirus pandemic, those experiencing hypoxia and who are at the highest risk of requiring mechanical ventilation.
DePuy Synthes*, in collaboration with LifeNet Health®, launches ViviGen Formable™ Cellular Bone Matrix**, a second generation cellular allograft used to assist in the formation of bone during spinal fusion surgery. ViviGen Formable augments the DePuy Synthes biomaterials portfolio and joins the first generation, ViviGen® Cellular Bone Matrix, which launched in late 2014. With both ViviGen and ViviGen Formable, surgeons may now choose a preferred handling option based on the needs of each surgical case.
Although more than two fifths of lung cancers are diagnosed in patients over 70, data from clinical trials on the safest and most effective treatments for this age group are scarce.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Chrystel Therese Venturini, MD 19020 33rd Ave W Ste 210, Lynnwood, WA 98036-4748 Ph: (425) 563-1500 | Dr Chrystel Therese Venturini, MD 3417 Ensign Rd Ne, Olympia, WA 98506-5064 Ph: (360) 493-4600 |
News Archive
Mylan Inc. today confirmed that its majority-owned subsidiary, Matrix Laboratories Ltd., has been sued by Daiichi Sankyo in connection with Amlodipine Besylate/Olmesartan Medoxomil Tablets, 5 mg/20 mg, 10 mg/20 mg, 5 mg/40 mg and 10 mg/40 mg, the generic version of Daiichi Sankyo's Azor Tablets.
Following positive preliminary data, Octapharma USA is extending funding for an investigator-initiated study (IIS) focused on treating the most critical patients at the heart of the coronavirus pandemic, those experiencing hypoxia and who are at the highest risk of requiring mechanical ventilation.
DePuy Synthes*, in collaboration with LifeNet Health®, launches ViviGen Formable™ Cellular Bone Matrix**, a second generation cellular allograft used to assist in the formation of bone during spinal fusion surgery. ViviGen Formable augments the DePuy Synthes biomaterials portfolio and joins the first generation, ViviGen® Cellular Bone Matrix, which launched in late 2014. With both ViviGen and ViviGen Formable, surgeons may now choose a preferred handling option based on the needs of each surgical case.
Although more than two fifths of lung cancers are diagnosed in patients over 70, data from clinical trials on the safest and most effective treatments for this age group are scarce.
› Verified 4 days ago
Dr. Kevin Joseph Reed, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 3417 Ensign Rd Ne, Olympia, WA 98506 Phone: 360-493-4609 Fax: 360-493-4603 | |
Dr. Lawrence Northwood Bennett, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3417 Ensign Rd Ne, Olympia, WA 98506 Phone: 360-493-4600 Fax: 360-493-4603 | |
Dr. Samuel J. Boynton, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3417 Ensign Rd Ne, Olympia, WA 98506 Phone: 360-493-4600 Fax: 360-493-4603 | |
Dr. Tariq Hesham Balawi, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3417 Ensign Rd Ne, Olympia, WA 98506 Phone: 360-493-4600 Fax: 360-493-4603 | |
Dr. Jabi Elijah Shriki, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 3417 Ensign Road Ne, Olympia, WA 98506 Phone: 360-493-4609 Fax: 360-493-4603 | |
Dr. Jack Mark Fields, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3417 Ensign Rd Ne, Olympia, WA 98506 Phone: 360-493-4600 Fax: 360-493-4603 | |
Dr. Christopher Brinson Hartness, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 413 Lilly Rd Ne, Olympia, WA 98506 Phone: 604-937-4603 Fax: 360-493-7253 |